OBALON THERAPEUTICS, INC. (NASDAQ:OBLN) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
meeting of stockholders (the Annual Meeting) on June 6, 2017. At
the Annual Meeting, the Companys stockholders voted on two
proposals, as described below. Each of the proposals was
described in detail in the Companys definitive proxy statement on
Schedule 14A filed with the U.S. Securities and Exchange
Commission on April 27, 2017. The vote totals noted below are
final voting results from the Annual Meeting.
Directors for a term of office expiring at the Companys 2020
annual meeting of stockholders and until their successors are
duly elected and qualified or until such directors earlier death,
resignation or removal.
|
Name
|
Votes For
|
Votes Withheld
|
Broker Non-Votes
|
|
Douglas Fisher, M.D.
|
10,851,642
|
1,274,041
|
1,187,673
|
|
Sharon Stevenson, DVM Ph.D.
|
10,910,488
|
1,215,195
|
1,187,673
|
the Companys independent registered public accounting firm for
the fiscal year ending December 31, 2017.
|
Votes For
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
|
13,309,404
|
1,600
|
2,352
|
About OBALON THERAPEUTICS, INC. (NASDAQ:OBLN)
Obalon Therapeutics, Inc. is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.
